A scientometric analysis and up-to-date review of nano-based drug delivery systems in glioblastoma treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018
2. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-201910.1093/neuonc/noac202 ↗
3. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.10.1056/NEJMoa043330 ↗
4. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology.10.7150/thno.40298 ↗
5. Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors.10.1016/j.drudis.2021.04.008 ↗
6. Nanocarrier-based drug combination therapy for glioblastoma.10.7150/thno.38147 ↗
7. Nanotechnology-based combinatorial anti-glioblastoma therapies: moving from terminal to treatable.10.3390/pharmaceutics14081697 ↗
8. Bionanoparticles in cancer imaging, diagnosis, and treatment.10.1002/VIW.20200027 ↗
9. Emerging trends and research foci of epithelial-mesenchymal transition in gliomas: a scientometric analysis and review.10.3389/fonc.2022.1015236 ↗
10. Immunotherapy in cervical cancer: from the view of scientometric analysis and clinical trials.10.3389/fimmu.2023.1094437 ↗
11. Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis.10.1016/j.jconrel.2022.10.023 ↗
12. Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020.10.1016/j.jconrel.2022.03.031 ↗
13. Research trend of nanoscience and nanotechnology – a bibliometric analysis of nano today10.1016/j.nantod.2021.101233 ↗
14. Recent advances of nanotechnology application in autoimmune diseases – a bibliometric analysis10.1016/j.nantod.2022.101694 ↗
15. Nanotechnology for the diagnosis and treatment of Alzheimer's disease: a bibliometric analysis10.1016/j.nantod.2022.101654 ↗
16. Harnessing nanotechnology for cardiovascular disease applications - a comprehensive review based on bibliometric analysis10.1016/j.nantod.2022.101453 ↗
17. Chen C. Visualizing and Exploring Scientific Literature with CiteSpace: An Introduction. Proceedings of the 2018 Conference on Human Information Interaction & Retrieval; New Brunswick, NJ, USA: Association for Computing Machinery; 2018. p. 369–70.10.1145/3176349.3176897 ↗
18. Emerging trends and new developments in information science: a document co-citation analysis (2009–2016)10.1007/s11192-018-2695-9 ↗
19. Global trends and characteristics of nano- and micro-bubbles research in environmental engineering over the past two decades: a scientometric analysis10.1016/j.scitotenv.2021.147362 ↗
20. Software survey: VOSviewer, a computer program for bibliometric mapping10.1007/s11192-009-0146-3 ↗
21. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace10.1517/14712598.2012.674507 ↗
22. The 2016 World Health Organization classification of tumors of the central nervous system: a summary10.1007/s00401-016-1545-1 ↗
23. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment10.1016/j.drup.2015.02.002 ↗
24. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
25. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art10.1016/j.jconrel.2016.02.026 ↗
26. Current state of immunotherapy for glioblastoma10.1038/s41571-018-0003-5 ↗
27. Temozolomide resistance in glioblastoma multiforme10.1016/j.gendis.2016.04.007 ↗
28. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
29. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain10.1093/neuonc/nov244 ↗
30. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles10.1038/s41467-018-04315-4 ↗
31. Current challenges and opportunities in treating glioblastoma10.1124/pr.117.014944 ↗
32. Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014)10.1517/14712598.2014.920813 ↗
33. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial10.1200/JCO.2005.04.5963 ↗
34. Emerging treatment strategies for glioblastoma multiforme10.15252/emmm.201302627 ↗
35. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy10.1016/j.jconrel.2021.07.003 ↗
36. Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme10.1016/j.jconrel.2022.08.024 ↗
37. a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.10.1634/theoncologist.5-2-144 ↗
38. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance10.1016/j.bbcan.2021.188616 ↗
39. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
40. methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas10.1038/cddis.2013.388 ↗
41. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers10.1016/j.ejpb.2021.08.011 ↗
42. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway10.1002/ijc.22804 ↗
43. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance10.1038/ncomms9904 ↗
44. Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound10.2147/IJN.S286221 ↗
45. Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance10.1080/17425247.2022.2124967 ↗
46. siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model
47. Nano-codelivery of temozolomide and siPD-L1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma10.1021/acsnano.1c09794 ↗
48. A nanoantidote alleviates glioblastoma chemotoxicity without efficacy compromise10.1021/acs.nanolett.1c01201 ↗
49. Progress in research on paclitaxel and tumor immunotherapy10.1186/s11658-019-0164-y ↗
50. Paclitaxel: application in modern oncology and nanomedicine-based cancer therapy10.1155/2021/3687700 ↗
51. Paclitaxel (Taxol) concentrations in brain tumor tissue10.1093/oxfordjournals.annonc.a058736 ↗
52. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors10.1093/jnci/87.14.1077 ↗
53. A comprehensive review on time-tested anticancer drug doxorubicin10.1016/j.lfs.2021.119527 ↗
54. Doxorubicin-induced cardiomyopathy10.1056/NEJM199809243391307 ↗
55. Doxorubicin: nanotechnological overviews from bench to bedside10.1016/j.drudis.2016.11.005 ↗
56. Epirubicin: is it like doxorubicin in breast cancer? A clinical review10.1016/j.breast.2011.12.012 ↗
57. Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma10.1080/2162402X.2016.1208876 ↗
58. Topoisomerase I inhibitors: camptothecins and beyond10.1038/nrc1977 ↗
59. Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise10.1016/j.ejmech.2021.113639 ↗
60. Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study10.1007/s11060-008-9774-3 ↗
61. Nitrosoureas in the management of malignant gliomas10.1007/s11910-015-0611-8 ↗
62. Molecular targeted therapy: treating cancer with specificity10.1016/j.ejphar.2018.07.034 ↗
63. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance10.1016/j.phrs.2021.105780 ↗
64. Comprehensive genomic characterization defines human glioblastoma genes and core pathways10.1038/nature07385 ↗
65. The somatic genomic landscape of glioblastoma.10.1016/j.cell.2013.09.034 ↗
66. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.10.1073/pnas.1219817110 ↗
67. Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'.10.1038/cddis.2016.318 ↗
68. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies10.1038/s41388-017-0045-7 ↗
69. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas10.1073/pnas.87.21.8602 ↗
70. Erlotinib: early clinical development in brain cancer10.1517/13543784.2014.918950 ↗
71. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
72. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma10.1158/1078-0432.CCR-12-1707 ↗
73. Ligand-independent EGFR signaling10.1158/0008-5472.CAN-15-0989 ↗
74. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma10.1093/annonc/mdp032 ↗
75. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status10.1186/s12885-015-1191-3 ↗
76. A phase 1 study of ABT-806 in subjects with advanced solid tumors10.1007/s10637-015-0234-6 ↗
77. Molecular targeted therapy of glioblastoma10.1016/j.ctrv.2019.101896 ↗
78. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma10.1200/JCO.2008.19.8721 ↗
79. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma10.1200/JCO.2008.16.3055 ↗
80. Lomustine and bevacizumab in progressive glioblastoma10.1056/NEJMoa1707358 ↗
81. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma10.1056/NEJMoa1308345 ↗
82. A randomized trial of bevacizumab for newly diagnosed glioblastoma10.1056/NEJMoa1308573 ↗
83. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed o6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial10.1200/JCO.2015.63.4691 ↗
84. Advances in the techniques and methodologies of cancer gene therapy
85. History of gene therapy10.1016/j.gene.2013.03.137 ↗
86. Recent trends in cancer therapy: a review on the current state of gene delivery10.1016/j.lfs.2021.119087 ↗
87. Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies10.1016/j.addr.2021.113999 ↗
88. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma10.1093/neuonc/nou355 ↗
89. Gene delivery in neuro-oncology10.1007/s11912-017-0628-z ↗
90. Immunotherapy in glioblastoma: current approaches and future perspectives10.3390/ijms23137046 ↗
91. Advances in immunotherapy for glioblastoma multiforme10.3389/fimmu.2022.944452 ↗
92. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence10.1186/s13045-022-01298-0 ↗
93. RNAi therapeutics: principles, prospects and challenges10.1016/j.addr.2007.03.005 ↗
94. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
95. Chitosan-based siRNA delivery systems10.1016/j.jconrel.2013.08.005 ↗
96. RNAi therapeutics: a potential new class of pharmaceutical drugs10.1038/nchembio839 ↗
97. The business of RNAi therapeutics10.1089/hum.2008.007 ↗
98. Nano-based delivery of RNAi in cancer therapy10.1186/s12943-017-0683-y ↗
99. Advances in immunotherapy for melanoma10.1186/s12916-016-0571-0 ↗
100. First-line immunotherapy for non-small-cell lung cancer10.1200/JCO.21.01497 ↗